Millennium Management’s Tourmaline Bio TRML Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-190,625
Closed -$9.12M 6465
2025
Q3
$9.12M Sell
190,625
-53,251
-22% -$1.48M ﹤0.01% 2472
2025
Q2
$3.9M Sell
243,876
-24,862
-9% -$403K ﹤0.01% 3241
2025
Q1
$4.09M Sell
268,738
-95,920
-26% -$1.54M ﹤0.01% 3061
2024
Q4
$7.4M Sell
364,658
-144,757
-28% -$3.65M ﹤0.01% 2453
2024
Q3
$13.1M Buy
+509,415
New +$8.5M 0.01% 1951
2024
Q2
Sell
-137,587
Closed -$3.15M 6544
2024
Q1
$3.15M Buy
137,587
+117,201
+575% +$4.13M ﹤0.01% 3321
2023
Q4
$534K Buy
20,386
+4,621
+29% +$92.5K ﹤0.01% 4603
2023
Q3
$443K Sell
15,765
-16,443
-51% -$481K ﹤0.01% 4736
2023
Q2
$979K Buy
+32,208
New +$822K ﹤0.01% 4065
2022
Q4
Sell
-5,323
Closed -$140K 7061
2022
Q3
$140K Buy
+5,323
New +$194K ﹤0.01% 5837

Millennium Management's TRML Position: Q4 2025 in Review

Millennium Management sold out of Tourmaline Bio (TRML) in Q4 2025, closing a stake of 190,625 shares — an estimated $9.12M sold.

Millennium Management first reported a position in TRML in Q3 2022 and held it in 10 quarters. The position peaked at $13.1M in Q3 2024. 0 funds tracked by Wall St. Rank hold TRML as of Q4 2025.

  • Millennium Management reported no remaining Tourmaline Bio position as of Q4 2025 after selling out during the quarter.
  • Millennium Management sold 190,625 Tourmaline Bio shares in Q4 2025, an estimated $9.12M.
  • Millennium Management first reported a position in Tourmaline Bio in Q3 2022 and held it in 10 quarters.
  • Millennium Management's Tourmaline Bio position peaked at $13.1M in Q3 2024.
  • 0 funds tracked by Wall St. Rank held Tourmaline Bio as of Q4 2025.

Based on Millennium Management's 13F filing for Q4 2025, filed 17 Feb 2026.